FDA

FDA
#Clinical trial #Drug discovery #FDA #Regulatory #SpliceBio #Stargardt disease

First-ever FDA IND for a protein splicing gene therapy

The US Food & Drug Administration (FDA) has cleared an investigational new drug (IND) application for SpliceBio’s lead programme SB-007, a clinical-stage therapeutic addressing the root genetic cause of Stargardt disease with the potential to treat all patients across all ABCA4 mutations. The SpliceBio study uses protein splicing to address… Read More

#News #Regulatory #Trending News

Heart monitor
#BridgeBio Pharma #Cardiovascular disease #FDA #Phase III trial

FDA approves Attruby to reduce cardio death in ATTR-CM patients

The US Food and Drug Administration (FDA) has approved BridgeBio Pharma’s Attruby (acoramidis), a near-complete (≥90%) stabiliser of Transthyretin (TTR).  It is approved for the treatment of adults with Transthyretin amyloid cardiomyopathy (ATTR-CM) to reduce cardiovascular death and cardiovascular-related hospitalisation.   The FDA approval is based on the ATTRibute-CM Phase III… Read More

#News #Regulatory

#AbbVie #Bristol Myers Squibb #Cerevel Therapeutics #FDA #Karuna Therapeutics #Neuroscience #Schizophrenia

Comment: Knock on effects of AbbVie’s failed schizophrenia trials

DDW’s Megan Thomas reflects on the impact of AbbVie’s failed schizophrenia trials. Earlier this month, AbbVie provided updates confirming that its two Phase II EMPOWER trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia who are experiencing an acute exacerbation of psychotic symptoms, have failed in… Read More

#Business & Investment #Exclusive Content #Opinion #Regulatory

#Applied Therapeutics #CNS #FDA #Genetic diseases #Rare disease

Patient groups urge FDA to reconsider govorestat rejection

The US Food and Drug Administration’s (FDA) decision not to approve govorestat, a central nervous system (CNS)-penetrant aldose reductase inhibitor (ARI) for Classic Galactosemia, has been met with criticism from patient groups.  Govorestat is the only investigational treatment to be evaluated for Galactosemia, a rare genetic disease that can be… Read More

#News #Regulatory #Trending News

FDA
#Bispecific Antibodies #FDA #Jazz Pharmaceuticals #Oncology

Bispecific antibody gets accelerated FDA approval for biliary tract cancer

The Food and Drug Administration (FDA) has granted accelerated approval to Jazz Pharmacuticals’ zanidatamab-hrii (Ziihera) a bispecific HER2-directed antibody.  It is approved for previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC), as detected by an FDA-approved test.  The FDA also approved VENTANA PATHWAY anti-HER-2/neu (4B5) Rabbit… Read More

#News #Regulatory

Gene therapy
#FDA #Gene therapy #Neurology #Neuroscience #PTC Therapeutics #Rare disease

FDA approves first gene therapy for rare genetic disorder

The US Food and Drug Administration (FDA) has approved Kebilidi (eladocagene exuparvovec-tneq), an adeno-associated virus vector-based gene therapy for the treatment of adult and paediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency. Aromatic L-amino acid decarboxylase deficiency is a rare genetic disorder that affects the production of some neurotransmitters,… Read More

#News #Regulatory

Child with eczema
#Artificial intelligence (AI) #Atopic dermatitis #Dermatology #Enveda #FDA #Plant-based

AI-discovered natural eczema medicine advances to clinical trials

The US Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for ENV-294 targeting atopic dermatitis and other inflammatory conditions. A Phase I clinical trial has since started for ENV-294, with the first patient dosed at the end of October. The first-in-class anti-inflammatory agent has demonstrated… Read More

#News #Regulatory

CAR-T therapy for leukaemia
#Autolus #CAR-T #Cell therapy #FDA #Immunotherapy #Leukaemia #Oncology

First FDA approval for new CAR-T therapy

The US Food and Drug Administration (FDA) has approved Autolus’ obecabtagene autoleucel (Aucatzyl), a CD19-directed genetically modified autologous T cell immunotherapy, for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL). The efficacy of obecabtagene autoleucel was evaluated in FELIX, an open-label, multicentre, single-arm trial that enrolled adults… Read More

#News #Regulatory #Trending News

Back pain
#Chronic pain #Drug abuse #FDA #Opioids #Painkillers #Protega

FDA approves abuse-deterrent immediate-release 10mg opioid

The US Food and Drug Administration (FDA) has approved Roxybond (oxycodone hydrochloride) 10mg for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. The approval makes Roxybond the first FDA-approved abuse-deterrent immediate release (IR) 10mg oxycodone formulation that is expected to… Read More

#News #Regulatory

#AI / data analytics / healthtech / informatics #Business #Digital solutions #Digital workflow #Drug development #Drug discovery #EMA #FDA #Marketing #Pharmaceuticals #Regulatory

New podcast: How to streamline regulatory approval

This is the latest episode of the free DDW narrated podcast, titled “How to streamline regulatory approval”, which covers two articles written for Volume 24 – Issue 1, Winter 2022/2023 of DDW. They are called: Quicker time to regulatory submission through improved data management and The three key stages to… Read More

#News #Regulatory

Diversity
#Clinical trials #Diversity #Drug development #Drug discovery #FDA #Inclusivity

Opinion: Are FDA plans enough to boost inclusivity within clinical trials?

DDW Editor Reece Armstrong examines whether recent FDA plans to boost diversity within clinical trials are enough to tackle the scale of the problem. In June this year, the US Food and Drug Administration (FDA) issued draft guidance designed to help boost the engagement of underrepresented communities within clinical trials.  … Read More

#Exclusive Content

FDA
#Astellas Pharma #Biomarkers #FDA #Immuno-oncology #Oncology

FDA approves CLDN18.2-targeted treatment for gastric cancer

The US Food and Drug Administration (FDA) has approved Vyloy (zolbetuximab-clzb) for locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma. It is approved in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adults whose tumours are claudin… Read More

#News #Regulatory

Tumour microenvironment
#FDA #Lymphoma #Oncology #Phase I trial #Recursion #Solid tumours

RBM39 degrader offers “promising approach” in solid tumours

TechBio Recursion will be launching a Phase I/II clinical trial of REC-1245 for the treatment of biomarker-enriched solid tumours and lymphoma, following the go-ahead from the US Food and Drug Administration (FDA). REC-1245 is a potent and selective RBM39 degrader with a potential first-in-class profile. Recursion identified the novel regulatory… Read More

#Cancer Research #News #Regulatory

#Antag Therapeutics #FDA #GLP-1 #Obesity #Phase I trial #Weight loss

FDA clears GIP receptor agonist trial in obese subjects

The US Food and Drug Administration (FDA) has accepted an Investigational New Drug (IND) application for Antag Therapeutics’ lead molecule AT-7687 for obesity. The company has announced plans to initiate a Phase I clinical trial, which will evaluate the safety, tolerability, and pharmacokinetics of AT-7687 in both healthy lean and… Read More

#News #Regulatory

Laboratory research
#Clinical trials #FDA #Funding #Orphan drugs #Rare disease

FDA awards grants to seven clinical trials for orphan products

The US Food and Drug Administration (FDA) has announced seven new clinical trial grants awarded under the Orphan Products Grants Program for clinical trials to address the unmet needs of people affected by rare diseases. In total, clinical researchers will receive approximately $17.2 million over the next four years. Newly… Read More

#News #Regulatory

Saline intravenous (iv) drip in a child's hand
#Cystic fibrosis #FDA #Paediatrics #Rare disease

Three drugs secure ‘rare paediatric disease designation’ in the US

Three drugs have been granted ‘rare paediatric disease designation’ (RPDD) in the US by the Food and Drug Administration (FDA). The FDA grants RPDD for serious or life-threatening diseases that affect fewer than 200,000 people in the United States and primarily affect patients less than 18 years of age. ETD001… Read More

#News #Regulatory